Intellipharmaceutics International Inc IPCIQ

Healthcare Biotechnology

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

GREY:IPCIQ - Post by User

Intellipharmaceutics International Inc > Advisor commitee vote and PDF

<< Previous

Bullboard Posts

Next >>

Comment by Priatomaon Jan 22, 2020 4:21pm

149 Views

Post# 30585167

RE:RE:Advisor commitee vote and PDF

BIGKAGAN, You pick a good point. if FDA consider Ad.Com vote only putting aside scientifica evaluation they should ban some of the existing Opioid products too. I see Some of the existing products in market just similar to IPCI. I know some of the existing product way worst compared to IPCI........... IPCI left no stone unturned whatever FDA asked to do and the company put their effort spending a lot of money and time. I believe at the end, FDA should value science NOT emotion. Good luck IPCI........

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue